Dianthus Therapeutics, Inc. (DNTH)
DNTH Stock Price Chart
Explore Dianthus Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze DNTH price movements and trends.
DNTH Company Profile
Discover essential business fundamentals and corporate details for Dianthus Therapeutics, Inc. (DNTH) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Jun 2018
Employees
92.00
Website
https://dianthustx.comCEO
Marino Garcia
Description
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
DNTH Financial Timeline
Browse a chronological timeline of Dianthus Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.85, while revenue estimate is $297.18k.
Earnings released on 5 May 2026
EPS came in at -$0.85 surpassing the estimated -$1.17 by +27.35%, while revenue for the quarter reached $463.00k , beating expectations by +14.71%.
Earnings released on 9 Mar 2026
EPS came in at -$1.43 falling short of the estimated -$0.98 by -45.92%, while revenue for the quarter reached $284.00k , missing expectations by -48.57%.
Earnings released on 5 Nov 2025
EPS came in at -$0.97 falling short of the estimated -$0.86 by -12.79%, while revenue for the quarter reached $396.00k , missing expectations by -31.25%.
Earnings released on 7 Aug 2025
EPS came in at -$0.88 falling short of the estimated -$0.86 by -2.33%, while revenue for the quarter reached $193.00k , missing expectations by -77.51%.
Earnings released on 12 May 2025
EPS came in at -$0.82 surpassing the estimated -$0.86 by +4.65%, while revenue for the quarter reached $1.16m , beating expectations by +44.13%.
Earnings released on 11 Mar 2025
EPS came in at -$0.81 surpassing the estimated -$0.85 by +4.71%, while revenue for the quarter reached $1.33m , beating expectations by +38.71%.
Earnings released on 7 Nov 2024
EPS came in at -$0.74 falling short of the estimated -$0.59 by -25.42%, while revenue for the quarter reached $2.17m , beating expectations by +193.06%.
Earnings released on 8 Aug 2024
EPS came in at -$0.51 surpassing the estimated -$0.55 by +6.46%, while revenue for the quarter reached $1.86m , beating expectations by +405.07%.
Earnings released on 9 May 2024
EPS came in at -$0.54 falling short of the estimated -$0.43 by -25.58%, while revenue for the quarter reached $874.00k , beating expectations by +88.26%.
Earnings released on 21 Mar 2024
EPS came in at -$0.71 surpassing the estimated -$1.11 by +36.04%, while revenue for the quarter reached $457.00k , missing expectations by -16.68%.
Earnings released on 9 Nov 2023
EPS came in at -$3.78 falling short of the estimated -$0.51 by -641.18%, while revenue for the quarter reached $924.00k , beating expectations by +269.60%.
Stock split effective on 12 Sept 2023
Shares were split 1 : 16 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 3 Aug 2023
EPS came in at -$3.12 falling short of the estimated -$0.80 by -290.00%, while revenue for the quarter reached $1.00m .
Earnings released on 15 May 2023
EPS came in at -$7.52 falling short of the estimated -$6.40 by -17.50%, while revenue for the quarter reached $476.00k .
Earnings released on 3 Nov 2022
EPS came in at -$4.32 surpassing the estimated -$4.64 by +6.90%, while revenue for the quarter reached $1.17m .
Earnings released on 4 Aug 2022
EPS came in at -$4.64 surpassing the estimated -$5.44 by +14.71%.
Earnings released on 16 May 2022
EPS came in at -$6.24 falling short of the estimated -$5.09 by -22.59%.
Earnings released on 8 Mar 2022
EPS came in at -$5.25 .
Earnings released on 4 Nov 2021
EPS came in at -$4.76 .
Earnings released on 5 Aug 2021
EPS came in at -$5.04 .
DNTH Stock Performance
Access detailed DNTH performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
